Mitogen-Activated Protein Kinase Signaling in Cancer Therapeutics

The mitogen-activated protein kinase (MAPK) cascade is a fundamental signalling module that transduces extracellular stimuli into diverse cellular outcomes, including proliferation, differentiation, survival and apoptosis. Aberrant activation of this pathway, most often through mutations in RAS or RAF kinases, underlies the development and progression of many malignancies. Therapeutic strategies have centred on inhibiting RAF kinases and their downstream effectors MEK and ERK, with several small-molecule inhibitors now approved for cancers harbouring BRAF or MEK mutations. Despite initial clinical success, adaptive resistance invariably emerges, driven by feedback reactivation, compensatory pathways such as PI3K-AKT or autophagy-mediated survival and secondary mutations. Recent advances extend beyond conventional inhibitors to include allele-specific KRAS covalent modulators and pan-KRAS compounds that stabilise the inactive conformation of multiple KRAS mutants. Genetic and pharmacological biosensors have further elucidated spatiotemporal dynamics of RAS activity in subcellular compartments, informing precision targeting. A growing emphasis on combination regimens aims to pre-empt resistance by co-targeting feedback loops and parallel survival pathways. Collectively, these approaches exemplify a shift towards mechanistically informed, adaptable therapies that integrate real-time biomarker feedback and exploit vulnerabilities in tumour signalling networks on a global scale.

Research from Nature Portfolio

One study reports a non-covalent inhibitor that preferentially binds inactive KRAS across a broad spectrum of oncogenic mutations. By preventing nucleotide exchange, the compound selectively suppresses downstream ERK signalling in KRAS-mutant cells and markedly reduces tumour growth in murine models without systemic toxicity. Another investigation describes computationally designed, genetically encoded biosensors that detect endogenous Ras activity and label proximal signalling partners at subcellular resolution. Application of these tools revealed novel regulators of oncogenic Ras assemblies and offers a platform for identifying context-specific therapeutic targets within intact cancer cells.

Mitogen-Activated Protein Kinase Signaling in Cancer Therapeutics publication trend

The graph below shows the total number of articles in mitogen-activated protein kinase signaling in cancer therapeutics across all publications each year (not limited to Nature Index journals).

Technical terms

Mitogen-Activated Protein Kinase (MAPK) cascade: A tiered series of kinases (RAF → MEK → ERK) that transmits extracellular signals to nuclear and cytosolic targets.

RAS: A family of small GTPases (e.g. KRAS, NRAS) that cycle between active and inactive states to regulate RAF kinase activation.

KRAS G12C mutation: A substitution at glycine 12 that enables selective covalent inhibitor binding to the inactive form of KRAS.

Pan-KRAS inhibitor: A compound designed to bind and inhibit multiple mutant KRAS isoforms by stabilising the inactive conformation.

Biosensor: A genetically encoded probe that reports on the activity or localisation of a target protein within living cells.

Autophagy: A lysosome-dependent degradation pathway that cancer cells can exploit to survive targeted therapy stress.

References

1. Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies. Signal Transduction and Targeted Therapy (2023).
2. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. Nature (2023).
3. Computationally designed sensors detect endogenous Ras activity and signaling effectors at subcellular resolution. Nature Biotechnology (2024).
4. Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity. International Journal of Molecular Sciences (2020).
5. KRAS mutation: from undruggable to druggable in cancer. Signal Transduction and Targeted Therapy (2021).